Pipeline

뒷 페이지 앞 페이지

Pipeline

New Drug

Disease Area

Code

Indication

Research

Preclinical

PhaseⅠ

PhaseⅡ

PhaseⅢ

NDA

Remark

Metabolic
Diseases

  • LR19052

  • LR19054

  • LR19051

  • LR19123

  • LR19018

  • LR19074
  • LR19021

  • LR19020

  • LR19131

  • Diabetes

  • Diabetes

  • Diabetes

  • Diabetes

  • Diabetes

  • Gout

  • Obesity

  • Obesity

  • Metabolic disease

Oncology

  • Cancer

  • Cancer

  • Cancer

  • Cancer

  • Cancer

Immunology

  • LR19055

  • LR19019
  • LR19025

  • LR19024

  • LR19030

  • Autoimmune disease

  • Autoimmune disease

  • Degenerative disease

  • Degenerative disease

  • Alopecia

  • combination drug (Korea)

  • (China)

  • combination drug (Thailand)

  • In partnership with

  • In partnership with

  • In partnership with

Medical Device and Vaccine

Aesthetics

  • LR19059

  • LR19059

  • Dermal filler

  • Dermal filler

Vaccine

  • LR19113

  • LR19122

  • LR19115

  • Polio

  • Diphtheriae,
    tetanus,
    pertussis,
    hepatitis B,
    meningitis,
    polio

  • Pneumococcus

  • Aesthetics

    Medical Device
    (China)

  • Aesthetics

    Medical Device
    (Europe)

  • Funded by

  • Funded by

Disease Area

Phases

Metabolic Diseases

LR19052

Diabetes

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

LR19054

Diabetes

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

LR19051

Diabetes

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

LR19123

Diabetes

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

LR19018

Diabetes

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

Gout

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

LR19021

Obesity

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

LR19020

Obesity

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

LR19131

Metabolic disease

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

Oncology

Cancer

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

Cancer

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

LR19129

Cancer

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

LR19031

Cancer

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

LR19023

Cancer

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

Immunology

LR19055

Autoimmune disease

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

Autoimmune disease

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

LR19025

Degenerative disease

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

LR19024

Degenerative disease

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

LR19030

Alopecia

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

Aesthetics

LR19059

Dermal filler

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

LR19059

Dermal filler

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

Vaccine

LR19113

Polio

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

LR19122

Diphtheriae, tetanus, pertussis, hepatitis B, meningitis, polio

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA

LR19115

Pneumococcus

  • Research
  • Preclinical
  • PhaseⅠ
  • PhaseⅡ
  • PhaseⅢ
  • NDA
  • Gout is a common and complex form of inflammatory arthritis, resulting from the deposition of monosodium urate monohydrate crystals. With persistent urate crystal deposition, gout may progress from acute episodic attacks to a disabling chronic deforming arthropathy, with destructive deposits of urate crystals (tophi) in bones, joints, subcutaneous tissue, and other organs. LC350189 is a novel non-purine selective inhibitor of Xanthine Oxidase (XO). XO is needed to successively oxidize both hypoxanthine and xanthine to uric acid. Hence, this agent reduces uric acid concentrations in serum by inhibiting the production of uric acid by XO inhibition.

    While the global gout therapeutics market is expected to reach a value of USD 8.5 billion by 2025 (CAGR: 16.1%), current therapies for chronic management of hyperuricemia in patients with gout either may not be used effectively due to titration requirement or potential safety issues. LC350189 has the potential to address the unmet clinical needs for safety and efficacy in gout treatment. LC350189 has shown good safety profiles in preclinical studies to support long-term clinical use and excellent efficacy in Phase I study. LC350189 lowered sUA when administered multiple ascending doses and appeared to be well-tolerated in normal healthy male subjects. There was no specific safety concern in Phase I study and preclinical study. The proposed indication of LC350189 based on the results of the clinical study conducted is treatment for chronic management of hyperuricemia in patients with gout.

    The Phase II study in the US will be carried out in late 2019.

    *LC350189 is a compound name for LR19074
  • LG Chem 새창열림
    *LC51-0255 is a compound name for LR19019

    LC51-0255 is a second generation, oral, selective sphingosine-1-phosphate (S1P) receptor modulator, a G protein coupled receptor with high selectivity for S1P1. S1P1 receptor agonists sequester circulating lymphocytes into secondary lymphoid organ, acting as functional antagonists by long-term internalization and degradation of S1P1 receptor, thereby alleviate autoimmune pathology. Inflammatory Bowel Diseases (IBD) is a type of autoimmune diseases – which is one of major health problems with more than 100 different types, and its heterogeneity leads to large number of non-responder treatments. Currently, there is no disease-modifying drug in the treatment options of IBD, and most drugs consist mainly of anti-inflammatory treatments. Given that IBD treatment requires lifelong maintenance, safety factors such as tolerance and toxicity will be a main concern for new drug development.  

    LC51-0255 is a new oral therapy for treatment of ulcerative colitis and crohn’s disease, two major IBD, and other autoimmune diseases. It showed rapid and dose-dependent lymphocyte reduction and good tolerability in Phase I study with healthy volunteers. Also, low risk of lung and/or liver toxicities was observed in animal toxicology study. LC51-0255 has broad therapeutic margin with no dose titration required.

    Its Phase I Multiple Ascending Dose (MAD) study is currently on-going and readout will be available in 3Q 2019. Global Phase II clinical trial Investigational New Drug submission is expected to be in late 2019.

  • LG Chem 새창열림
    *CUE-101 is a compound name for LR19127

    CUE-101 is a fusion protein designed to activate and expand tumor-specific T cells, directly in the patient’s body, that target Human Papilloma 16 (HPV16)-driven malignancies. It contains IL-2 and a pMHC composed of HLA-A*02:01 complexed with a dominant peptide derived from  the E7 protein of human papilloma virus 16 (HPV 16-E7). CUE-101 is the lead immuno-oncology drug developed within the IL-2 based CUE-100 framework from Cue Biopharma’s novel Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform technology. In November 2018, LG Chem Life Sciences partnered with Cue Biopharma to develop and commercialize cancer immunotherapy drugs based on the Immuno-STAT platform technology. 

    HPV cancers account for more than 20,000 deaths each year in the US and Europe. The majority of these cancers are driven by HPV 16 which carries the E7 antigen targeted by CUE-101. Despite treatment with current standards of care, approximately 50% of patients with advanced disease will experience recurrence and significant quality of life impact. Patients with HPV-related head and neck, cervical and genitoanal cancers represent an important unmet clinical need and underscore the opportunity for promising new therapeutics.

    In preclinical studies, CUE-101 has demonstrated selective binding and preferential activation and expansion of antigen-specific T cells, dose-dependent effector cytokine production and inhibition of tumor growth both as a monotherapy and in combination with a PD-1 inhibitor.

    The Investigational New Drug (IND) application for CUE-101 was accepted by the U.S. Food and Drug Administration (FDA) in May 2019. The open-label, multi-center Phase I trial for Head and Neck Squamous Cell Carcinoma (HNSCC) patients is expected to be initiated accordingly.

    In addition to the CUE-101 program, CUE-102 targeting WT-1 and CUE-103 (TBD) are being developed through this partnership.

  • LG Chem 새창열림
    *PDC lung is a compound name for LR19125

    PDC* lung is an off-the shelf cancer vaccine of potent Ag-specific CD8+ T cell inducer based on a proprietary cell line of Plasmacytoid Dendritic Cells (PDC* line) originating from the French-Belgian biotech company PDC* line Pharma. PDC* lung consists of PDC* line loaded with HLA-A*02:01-restricted peptides derived from 6 antigens broadly expressed in Non-Small-Cell Lung Cancer (NSCLC). LG Chem in-licensed PDC* line’s anti-cancer vaccine in March 2019.

    PDC* lung is our leading product for NSCLC. 2.1 million new cases of lung cancer were diagnosed worldwide in 2018, and it was responsible for and 1.8 million deaths (source IARC). Lung cancer is therefore the most frequently diagnosed cancer and the leading cause of cancer mortality. About 60% of patients are diagnosed with locally advanced (stage IIIb) or metastatic (stage IV) cancer; prognosis is poor (median survival of 8-13 months).

    PDC* line is highly potent in priming and boosting fully functional antitumor CTL displaying a strong cytotoxic activity against tumor cells, and it is synergetic with the use of anti-PD-1 immune checkpoint inhibitors.  Robust results already obtained for PDC* line provide a preclinical validation, as well as ex vivo results on blood samples of lung cancer patients. An approval was granted in May, 2019 to PDC* line Pharma to launch in France and in Belgium PDC-LUNG-101 trial, an open-label, dose-escalation, Phase I/II study to assess the safety, the tolerability, the immunogenicity and the preliminary clinical activity of the therapeutic cancer vaccine, PDC* lung01, associated with or without anti-PD-1 treatment in patients with non-small-cell lung cancer.